<!doctype html><html lang=en-us dir=ltr><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge,chrome=1"><meta name=robots content="index,follow"><meta name=googlebot content="index,follow"><link rel=sitemap type=application/xml title=Sitemap href=https://nexus-security.github.io/sitemap.xml><meta property="og:type" content="article"><meta name=author content="0x000216"><meta property="og:locale" content="en"><meta name=language content="English"><base href=https://Nexus-Security.github.io/posts/2016-09-09-aippi-uk-event-report-roundup-of-2019/><link rel=icon href=/fav.ico type=image/x-icon><link rel=alternate type=application/rss+xml title=RSS href=https://nexus-security.github.io/index.xml><meta name=viewport content="width=device-width,initial-scale=1"><meta name=description content="The AmeriKat peering into 2020 and what
this year&amp;rsquo;s patent cases will hold&amp;hellip;
While the AmeriKat was coughing herself across the Atlantic home for Christmas, other IP lawyers were making their ways across London&amp;rsquo;s twinkle light illuminated pavements to AIPPI&amp;rsquo;s annual Patent Round-Up held at Hogan Lovells&amp;rsquo; London office. The AmeriKat turned to friend Joost Duijm (Hogan Lovells) to sum up proceedings for IPKat readers.
Over to Joost: &amp;ldquo;Introduction"><title>AIPPI UK Event Report: Roundup of 2019's Patent Cases</title><link rel=canonical href=https://Nexus-Security.github.io/posts/2016-09-09-aippi-uk-event-report-roundup-of-2019/><link rel=stylesheet href=/scss/style.min.1f3200acb41251d94439982f0ccc8f6599efd31eaa9b4d6412b905bc3d5fa0b8.css><meta property="og:title" content="AIPPI UK Event Report:  Roundup of 2019's Patent Cases"><meta property="og:description" content="The AmeriKat peering into 2020 and what
this year&amp;rsquo;s patent cases will hold&amp;hellip;
While the AmeriKat was coughing herself across the Atlantic home for Christmas, other IP lawyers were making their ways across London&amp;rsquo;s twinkle light illuminated pavements to AIPPI&amp;rsquo;s annual Patent Round-Up held at Hogan Lovells&amp;rsquo; London office. The AmeriKat turned to friend Joost Duijm (Hogan Lovells) to sum up proceedings for IPKat readers.
Over to Joost: &amp;ldquo;Introduction"><meta property="og:url" content="https://Nexus-Security.github.io/posts/2016-09-09-aippi-uk-event-report-roundup-of-2019/"><meta property="og:site_name" content="0x000216"><meta property="og:type" content="article"><meta property="article:section" content="Posts"><meta property="article:published_time" content="2020-01-07T16:26:00+01:00"><meta property="article:modified_time" content="2020-01-07T16:26:00+01:00"><meta name=twitter:title content="AIPPI UK Event Report:  Roundup of 2019's Patent Cases"><meta name=twitter:description content="The AmeriKat peering into 2020 and what
this year&amp;rsquo;s patent cases will hold&amp;hellip;
While the AmeriKat was coughing herself across the Atlantic home for Christmas, other IP lawyers were making their ways across London&amp;rsquo;s twinkle light illuminated pavements to AIPPI&amp;rsquo;s annual Patent Round-Up held at Hogan Lovells&amp;rsquo; London office. The AmeriKat turned to friend Joost Duijm (Hogan Lovells) to sum up proceedings for IPKat readers.
Over to Joost: &amp;ldquo;Introduction"><link rel="shortcut icon" href=/fav.ico></head><body class=article-page><script>(function(){const e="StackColorScheme";localStorage.getItem(e)||localStorage.setItem(e,"light")})()</script><script>(function(){const t="StackColorScheme",e=localStorage.getItem(t),n=window.matchMedia("(prefers-color-scheme: dark)").matches===!0;e=="dark"||e==="auto"&&n?document.documentElement.dataset.scheme="dark":document.documentElement.dataset.scheme="light"})()</script><div class="container main-container flex on-phone--column extended"><aside class="sidebar left-sidebar sticky"><button class="hamburger hamburger--spin" type=button id=toggle-menu aria-label="Toggle Menu">
<span class=hamburger-box><span class=hamburger-inner></span></span></button><header><figure class=site-avatar><a href=/><img src=/img/avatar_hue825486955cd7c56d95e38b4bd2a8e3c_229979_300x0_resize_box_3.png width=300 height=300 class=site-logo loading=lazy alt=Avatar></a></figure><div class=site-meta><h1 class=site-name><a href=/>0x000216</a></h1><h2 class=site-description>Where Do Russian Hackers Store Their Exploits? 🤓 /ussr/bin/ 😋</h2></div></header><ol class=social-menu><li><a href=https://github.com/Nexus-Security target=_blank title=GitHub><svg width="72" height="72" viewBox="0 0 72 72" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="M36 72c19.882251.0 36-16.117749 36-36 0-19.882251-16.117749-36-36-36-19.882251 365231026e-23-36 16.117749-36 36C24348735e-22 55.882251 16.117749 72 36 72z" fill="#3e75c3"/><path d="M35.9985 12C22.746 12 12 22.7870921 12 36.096644c0 10.6440272 6.876 19.6751861 16.4145 22.8617681C29.6145 59.1797862 30.0525 58.4358488 30.0525 57.7973276 30.0525 57.2250681 30.0315 55.7100863 30.0195 53.6996482c-6.6765 1.4562499-8.085-3.2302544-8.085-3.2302544-1.0905-2.7829884-2.664-3.5239139-2.664-3.5239139C17.091 45.4500754 19.4355 45.4801943 19.4355 45.4801943c2.4075.1701719 3.675 2.4833051 3.675 2.4833051 2.142 3.6820383 5.6175 2.6188404 6.9855 2.0014024C30.3135 48.4077535 30.9345 47.3460615 31.62 46.7436831 26.2905 46.1352808 20.688 44.0691228 20.688 34.8361671c0-2.6308879.9345-4.781379 2.4705-6.4665327C22.911 27.7597262 22.0875 25.3110578 23.3925 21.9934585c0 0 2.016-.6475568 6.6 2.4697516C31.908 23.9285993 33.96 23.6620468 36.0015 23.6515052 38.04 23.6620468 40.0935 23.9285993 42.0105 24.4632101c4.581-3.1173084 6.5925-2.4697516 6.5925-2.4697516C49.9125 25.3110578 49.089 27.7597262 48.8415 28.3696344 50.3805 30.0547881 51.309 32.2052792 51.309 34.8361671c0 9.2555448-5.6115 11.29309-10.9575 11.8894446.860999999999997.7439374 1.629 2.2137408 1.629 4.4621184C41.9805 54.4089489 41.9505 57.0067059 41.9505 57.7973276 41.9505 58.4418726 42.3825 59.1918338 43.6005 58.9554002 53.13 55.7627944 60 46.7376593 60 36.096644 60 22.7870921 49.254 12 35.9985 12" fill="#fff"/></g></svg></a></li><li><a href=mailto:0x000216@gmail.com target=_blank title=Email><svg id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512"><path style="fill:#e6f3ff" d="M512 105.739v300.522c0 27.715-22.372 50.087-50.087 50.087H50.087C22.372 456.348.0 433.976.0 406.261V105.739c0-.89.0-1.781.111-2.671 1.336-25.6 21.704-45.969 47.304-47.304.89-.111 1.781-.111 2.671-.111h411.826c.89.0 1.892.0 2.783.111 25.489 1.336 45.857 21.704 47.193 47.193C512 103.847 512 104.849 512 105.739z"/><path style="fill:#cfdbe6" d="M464.696 55.763c-.892-.111-1.891-.111-2.783-.111H256v400.696h205.913c27.715.0 50.087-22.372 50.087-50.087V105.739c0-.89.0-1.892-.111-2.783C510.553 77.468 490.184 57.099 464.696 55.763z"/><path style="fill:#ff4b26" d="M511.889 102.957c-1.336-25.489-21.704-45.857-47.193-47.193C382.89 137.569 336.951 183.509 256 264.459 225.291 233.732 77.61 85.958 47.416 55.763c-25.6 1.336-45.969 21.704-47.304 47.304C0 103.958.0 104.849.0 105.739v300.522c0 27.715 22.372 50.087 50.087 50.087h16.696V169.739l165.621 165.51c6.456 6.567 15.026 9.795 23.597 9.795 8.57.0 17.141-3.228 23.597-9.795l165.621-165.621v286.72h16.696c27.715.0 50.087-22.372 50.087-50.087V105.739C512 104.849 512 103.847 511.889 102.957z"/><path style="fill:#d93f21" d="M279.596 335.249l165.621-165.621v286.72h16.696c27.715.0 50.087-22.372 50.087-50.087V105.739c0-.89.0-1.892-.111-2.783-1.336-25.489-21.704-45.857-47.193-47.193C382.891 137.569 336.951 183.509 256 264.459v80.584C264.57 345.043 273.141 341.816 279.596 335.249z"/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/></svg></a></li><li><a href=https://nexus-security.github.io/index.xml target=_blank title=RSS><svg id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512"><path style="fill:#f78c20" d="M78.333 355.334C35.14 355.334.0 390.474.0 433.667S35.14 512 78.333 512s78.333-35.14 78.333-78.333-35.14-78.333-78.333-78.333z"/><g><path style="fill:#ffa929" d="M78.333 381.445c-28.795.0-52.222 23.427-52.222 52.222s23.427 52.222 52.222 52.222 52.222-23.427 52.222-52.222-23.427-52.222-52.222-52.222z"/><path style="fill:#ffa929" d="M477.918 264.861c-21.843-51.641-53.111-98.019-92.936-137.842-39.824-39.824-86.201-71.093-137.843-92.935C193.669 11.468 136.874.0 78.333.0c-4.807.0-8.704 3.897-8.704 8.704v85.519c0 4.807 3.897 8.704 8.704 8.704 182.37.0 330.74 148.369 330.74 330.74.0 4.807 3.897 8.704 8.704 8.704h85.52c4.807.0 8.704-3.897 8.704-8.704C512 375.126 500.533 318.331 477.918 264.861z"/><path style="fill:#ffa929" d="M78.333 163.853c-4.807.0-8.704 3.897-8.704 8.704v95.74c0 4.807 3.897 8.704 8.704 8.704 86.386.0 156.666 70.281 156.666 156.666.0 4.807 3.897 8.704 8.704 8.704h95.74c4.807.0 8.704-3.897 8.704-8.704.0-72.07-28.065-139.826-79.027-190.787-50.961-50.961-118.717-79.027-190.787-79.027z"/></g><g><path style="fill:#f78c20" d="M78.333 242.186c-2.918.0-5.817.076-8.704.206v25.905c0 4.807 3.897 8.704 8.704 8.704 86.386.0 156.666 70.281 156.666 156.666.0 4.807 3.897 8.704 8.704 8.704h25.905c.129-2.886.206-5.786.206-8.704.0-105.752-85.729-191.481-191.481-191.481z"/><path style="fill:#f78c20" d="M78.333 68.113c-2.91.0-5.81.042-8.704.11v26.001c0 4.807 3.897 8.704 8.704 8.704 182.37.0 330.74 148.369 330.74 330.74.0 4.807 3.897 8.704 8.704 8.704h26.001c.067-2.894.11-5.793.11-8.704C443.887 231.777 280.223 68.113 78.333 68.113z"/></g><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/></svg></a></li><li><a href target=_blank title=Slack><svg width="256" height="256" viewBox="0 0 256 256" xmlns="http://www.w3.org/2000/svg" preserveAspectRatio="xMidYMid"><path d="M165.964 15.838c-3.89-11.975-16.752-18.528-28.725-14.636-11.975 3.89-18.528 16.752-14.636 28.725l58.947 181.365c4.048 11.187 16.132 17.473 27.732 14.135 12.1-3.483 19.475-16.334 15.614-28.217L165.964 15.838" fill="#dfa22f"/><path d="M74.626 45.516C70.734 33.542 57.873 26.989 45.9 30.879 33.924 34.77 27.37 47.631 31.263 59.606l58.948 181.366c4.047 11.186 16.132 17.473 27.732 14.132 12.099-3.481 19.474-16.332 15.613-28.217L74.626 45.516" fill="#3cb187"/><path d="M240.162 166.045c11.975-3.89 18.526-16.75 14.636-28.726-3.89-11.973-16.752-18.527-28.725-14.636L44.708 181.632c-11.187 4.046-17.473 16.13-14.135 27.73 3.483 12.099 16.334 19.475 28.217 15.614l181.372-58.93" fill="#ce1e5b"/><path d="M82.508 217.27l43.347-14.084-14.086-43.352-43.35 14.09 14.089 43.347" fill="#392538"/><path d="M173.847 187.591c16.388-5.323 31.62-10.273 43.348-14.084l-14.088-43.36-43.35 14.09 14.09 43.354" fill="#bb242a"/><path d="M210.484 74.706c11.974-3.89 18.527-16.751 14.637-28.727-3.89-11.973-16.752-18.526-28.727-14.636L15.028 90.293C3.842 94.337-2.445 106.422.896 118.022c3.481 12.098 16.332 19.474 28.217 15.613l181.371-58.93" fill="#72c5cd"/><path d="M52.822 125.933c11.805-3.836 27.025-8.782 43.354-14.086-5.323-16.39-10.273-31.622-14.084-43.352l-43.36 14.092 14.09 43.346" fill="#248c73"/><path d="M144.16 96.256l43.356-14.088a546179.21 546179.21.0 00-14.089-43.36L130.07 52.9l14.09 43.356" fill="#62803a"/></svg></a></li><li><a href=https://www.minds.com/0x000216/ target=_blank title=Minds><svg id="Capa_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512"><g><g><path style="fill:#ffe1b2" d="M256 33.085C245.078 13.38 224.079.0 2e2.0c-23.781.0-45.57 13.293-56.594 34.184C115.711 41.602 96 66.977 96 96c0 .059.0.113.0.172-9.977 7.512-16 19.301-16 31.828.0 1.316.078 2.637.234 3.992C60.211 145.266 48 167.758 48 192c0 14.07 4.039 27.543 11.719 39.262C57.273 236.512 56 242.207 56 248c0 2.738.281 5.445.828 8.098C36.672 267.308 24 288.539 24 312c0 27.973 18.305 52.34 44.109 60.785C65.398 378.828 64 385.324 64 392c0 21.098 13.805 39.508 33.539 45.727C103.891 466.746 129.828 488 160 488c4.617.0 9.227-.512 13.766-1.527C181.992 502 198.141 512 216 512c16.687.0 31.396-8.567 40-21.523V33.085z"/></g><g><g><path style="fill:#ffb980" d="M264 256c-4.422.0-8-3.582-8-8 0-22.055-17.945-40-40-40-8.008.0-15.734 2.355-22.336 6.812-3.023 2.043-7.055 1.781-9.797-.652-3.156-2.809-8.477-6.16-15.867-6.16-4.422.0-8-3.582-8-8s3.578-8 8-8c7.711.0 15.234 2.293 21.719 6.539C197.773 194.246 206.758 192 216 192c30.875.0 56 25.121 56 56C272 252.418 268.422 256 264 256z"/></g></g><g><g><path style="fill:#ffb980" d="M120 120c18.977.0 36.875 7.312 50.414 20.594 3.141 3.09 8.203 3.047 11.312-.109 3.094-3.152 3.047-8.219-.109-11.312C165.07 112.941 143.187 104 120 104c-13.046.0-25.395 2.93-36.542 8.046C81.253 117.019 80 122.423 80 128c0 1.316.078 2.637.234 3.992-.094.062-.173.139-.267.202C91.423 124.501 105.193 120 120 120z"/></g></g><g><g><path style="fill:#ffb980" d="M216 360c0-4.418-3.578-8-8-8s-8 3.582-8 8c0 17.645-14.352 32-32 32-14.211.0-26.82-9.648-30.664-23.465-.703-2.512-2.578-4.523-5.039-5.395-2.453-.871-5.188-.492-7.305 1.02C114.094 371.906 101.305 376 88 376c-6.948.0-13.625-1.149-19.894-3.207-2.214 4.939-3.501 10.19-3.916 15.586C71.714 390.73 79.711 392 88 392c13.297.0 26.187-3.266 37.773-9.52C133.969 397.894 150.141 408 168 408c26.469.0 48-21.531 48-48z"/></g></g><g><path style="fill:#fdc88e" d="M488 312c0-23.461-12.672-44.691-32.828-55.902.547-2.652.828-5.359.828-8.098.0-5.793-1.273-11.488-3.719-16.738C459.961 219.543 464 206.07 464 192c0-24.242-12.211-46.734-32.234-60.008.156-1.355.234-2.676.234-3.992.0-12.527-6.023-24.316-16-31.828.0-.059.0-.113.0-.172.0-29.023-19.711-54.398-47.406-61.816C357.57 13.293 335.781.0 312 0c-24.08.0-45.078 13.38-56 33.085v457.391C264.604 503.433 279.313 512 296 512c17.859.0 34.008-10 42.234-25.527C342.773 487.488 347.383 488 352 488c30.172.0 56.109-21.254 62.461-50.273C434.195 431.508 448 413.097 448 392c0-6.676-1.398-13.172-4.109-19.215C469.695 364.34 488 339.973 488 312z"/></g><g><path style="fill:#f8ab6b" d="M272.008 151.199C272 151.465 272 151.734 272 152c0 26.469 21.531 48 48 48s48-21.531 48-48c0-4.418-3.578-8-8-8s-8 3.582-8 8c0 17.645-14.352 32-32 32s-32-14.355-32-32c0-2.184.219-4.359.656-6.465.492-2.395-.133-4.883-1.703-6.754-1.57-1.871-4.016-3.066-6.352-2.859-.453.012-.891.059-.602.078-13.234.0-24-10.766-24-24v31.813C260.673 147.348 266.061 149.988 272.008 151.199z"/></g><g><path style="fill:#f8ab6b" d="M296 328c9.242.0 18.219-2.246 26.281-6.539C328.765 325.707 336.289 328 344 328c4.422.0 8-3.582 8-8s-3.578-8-8-8c-7.391.0-12.711-3.352-15.867-6.16-2.742-2.434-6.766-2.695-9.797-.656C311.726 309.644 304 312 296 312c-22.055.0-40-17.945-40-40v39.116C266.174 321.517 280.337 328 296 328z"/></g><g><g><path style="fill:#f8ab6b" d="M431.765 131.992c.156-1.355.234-2.676.234-3.992.0-5.577-1.253-10.981-3.458-15.954C417.395 106.93 405.046 104 392 104c-4.422.0-8 3.582-8 8s3.578 8 8 8c14.807.0 28.577 4.501 40.032 12.194C431.939 132.131 431.859 132.054 431.765 131.992z"/></g></g><g><g><path style="fill:#f8ab6b" d="M447.81 388.38c-.415-5.396-1.702-10.647-3.916-15.586C437.624 374.85 430.948 376 424 376c-13.578.0-26.594-4.266-37.641-12.332-2.07-1.5-4.719-1.93-7.133-1.168-2.43.77-4.344 2.648-5.164 5.059C369.101 382.176 355.414 392 340 392c-4.422.0-8 3.582-8 8s3.578 8 8 8c18.875.0 35.961-10.191 45.094-26.156C396.976 388.512 410.258 392 424 392 432.288 392 440.285 390.73 447.81 388.38z"/></g></g></g><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/></svg></a></li><li><a href=https://www.buymeacoffee.com/0x000216 target=_blank title=Coffee><svg id="Capa_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" viewBox="0 0 340 340" style="enable-background:new 0 0 340 340"><g id="XMLID_18_"><polygon id="XMLID_138_" style="fill:#dedde0" points="76.429,290 80,340 170,340 170,290"/><polygon id="XMLID_169_" style="fill:#dedde0" points="170,80 61.429,80 65,130 170,130"/><polygon id="XMLID_197_" style="fill:#acabb1" points="170,290 170,340 260,340 263.571,290"/><polygon id="XMLID_221_" style="fill:#acabb1" points="170,80 170,130 275,130 278.571,80"/><path id="XMLID_222_" style="fill:#ffda44" d="M170 260c-22.091.0-40-22.386-40-50s17.909-50 40-50v-30H65 50l10 160h16.429H170V260z"/><path id="XMLID_33_" style="fill:#ff9811" d="M170 130v30c22.091.0 40 22.386 40 50s-17.909 50-40 50v30h93.571H280l10-160h-15H170z"/><path id="XMLID_223_" style="fill:#50412e" d="M210 210c0-27.614-17.909-50-40-50v1e2c22.091.0 40-22.386 40-50z"/><path id="XMLID_224_" style="fill:#786145" d="M130 210c0 27.614 17.909 50 40 50V160c-22.091.0-40 22.386-40 50z"/><polygon id="XMLID_225_" style="fill:#50412e" points="278.571,80 300,80 300,40 260,40 260,0 80,0 80,40 40,40 40,80 61.429,80 170,80"/></g><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/><g/></svg></a></li></ol><ol class=menu id=main-menu><li><a href=/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-home" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><polyline points="5 12 3 12 12 3 21 12 19 12"/><path d="M5 12v7a2 2 0 002 2h10a2 2 0 002-2v-7"/><path d="M9 21v-6a2 2 0 012-2h2a2 2 0 012 2v6"/></svg><span>Home</span></a></li><li><a href=/about/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-user" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="12" cy="7" r="4"/><path d="M6 21v-2a4 4 0 014-4h4a4 4 0 014 4v2"/></svg><span>About Us</span></a></li><li><a href=/termsofservice/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-pencil" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z" fill="none"/><path d="M4 20h4L18.5 9.5a1.5 1.5.0 00-4-4L4 16v4"/><line x1="13.5" y1="6.5" x2="17.5" y2="10.5"/></svg><span>Terms Of Service</span></a></li><li><a href=/privacypolicy/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-archive" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><rect x="3" y="4" width="18" height="4" rx="2"/><path d="M5 8v10a2 2 0 002 2h10a2 2 0 002-2V8"/><line x1="10" y1="12" x2="14" y2="12"/></svg><span>Privacy Policy</span></a></li><li><a href=/disclaimer/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-link" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><path d="M10 14a3.5 3.5.0 005 0l4-4a3.5 3.5.0 00-5-5l-.5.5"/><path d="M14 10a3.5 3.5.0 00-5 0l-4 4a3.5 3.5.0 005 5l.5-.5"/></svg><span>Disclaimer</span></a></li><li><a href=/contact/><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-mail" width="44" height="44" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z" fill="none"/><rect x="3" y="5" width="18" height="14" rx="2"/><polyline points="3 7 12 13 21 7"/></svg><span>Contact Us</span></a></li><div class=menu-bottom-section><li id=dark-mode-toggle><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-toggle-left" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="8" cy="12" r="2"/><rect x="2" y="6" width="20" height="12" rx="6"/></svg><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-toggle-right" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="16" cy="12" r="2"/><rect x="2" y="6" width="20" height="12" rx="6"/></svg><span>Dark Mode</span></li></div></ol></aside><main class="main full-width"><article class=main-article><header class=article-header><div class=article-details><div class=article-title-wrapper><h2 class=article-title><a href=/posts/2016-09-09-aippi-uk-event-report-roundup-of-2019/>AIPPI UK Event Report: Roundup of 2019's Patent Cases</a></h2></div><footer class=article-time><div><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-calendar-time" width="56" height="56" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><path d="M11.795 21H5a2 2 0 01-2-2V7a2 2 0 012-2h12a2 2 0 012 2v4"/><circle cx="18" cy="18" r="4"/><path d="M15 3v4"/><path d="M7 3v4"/><path d="M3 11h16"/><path d="M18 16.496V18l1 1"/></svg><time class=article-time--published>Jan 07, 2020</time></div><div><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-clock" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="12" cy="12" r="9"/><polyline points="12 7 12 12 15 15"/></svg><time class=article-time--reading>10 minute read</time></div></footer></div></header><section class=article-content><p><a class=link href=https://1.bp.blogspot.com/-JGKvn09uK78/XhShi-hRtHI/AAAAAAAAGpY/YWh2lLCIx4EdAVQxsITB3ylwE-w68Hr9ACLcBGAsYHQ/s1600/Cat%2Btwinkle.jpg target=_blank rel=noopener><img src=https://1.bp.blogspot.com/-JGKvn09uK78/XhShi-hRtHI/AAAAAAAAGpY/YWh2lLCIx4EdAVQxsITB3ylwE-w68Hr9ACLcBGAsYHQ/s320/Cat%2Btwinkle.jpg loading=lazy></a></p><p><em>The AmeriKat peering into 2020 and what<br>this year&rsquo;s patent cases will hold&mldr;</em></p><p><strong>While the AmeriKat was coughing herself across the Atlantic</strong> home for Christmas, other IP lawyers were making their ways across London&rsquo;s twinkle light illuminated pavements to AIPPI&rsquo;s annual Patent Round-Up held at Hogan Lovells&rsquo; London office.  The AmeriKat turned to friend <strong>Joost Duijm</strong> (<a class=link href=https://www.hoganlovells.com/en/duijm-joost target=_blank rel=noopener><strong>Hogan Lovells</strong></a>) to sum up proceedings for IPKat readers.</p><p>Over to Joost: </p><p>&ldquo;<strong>Introduction</strong></p><p>Christmas came early this year! Because on 18 December 2019 the UK Group of AIPPI held its annual patent round-up event. The highlights of 2019&rsquo;s patent cases were presented by barrister, <strong><a class=link href=http://www.8newsquare.co.uk/members-of-chambers/Andrew+Lykiardopoulos+QC target=_blank rel=noopener>Andrew Lykiardopoulos</a></strong> QC, at the offices of Hogan Lovells LLP in London. Andrew&rsquo;s presentation was in the form of a lovely Christmas dinner, beginning with some tasty starters and finishing with a few delightful mince pies. Flying over from the other side of the Canal, this Kat lover was here to report for those who were too actively committed in other Christmas festivities.</p><p>Andrew kicked off with some statistics of 2019:</p><p>- The UK High Court rendered ten judgments regarding the contested validity of a patent. Of those ten, one patent was upheld by the court.</p><p>- The UK Court of Appeal rendered five judgments regarding the contested validity of a patent. Of those five, three patents were upheld by the court.</p><p>- The UK Supreme court rendered one judgment regarding the contested validity of a patent. In this judgment, the patent was held invalid.</p><p>Andrew concludes that 2019 was not the easiest year for patentees.</p><p>**The starters **</p><p><em>(1) Added matter and summary judgment</em></p><p>In <em>Novartis v Dr Reddy&rsquo;s</em> <a class=link href=https://drive.google.com/file/d/1AL2AOjgaZB9PJNxrgkVlRuRd-IDiEQZr/view target=_blank rel=noopener><strong>[2019] EWHC 92</strong></a>, the UK judge (Birss J) ruled on added matter. The case was initiated by Novartis&rsquo; application for an interim injunction on the basis of its patent. Dr. Reddy’s responded with an application for summary judgment on its counterclaim for revocation. It argued that the patent was invalid for the reasons given by the opposition division of the EPO, which had revoked the patent solely on the basis of added matter.</p><p>Birss J, however, ruled that <a class=link href="https://register.epo.org/application?documentId=E2A2WD5I6328DSU&number=EP10174983&lng=en&npl=false" target=_blank rel=noopener><strong>the decision of the OD</strong></a> &ldquo;appears to take an unduly technical approach which has lost sight of the disclosure of the document as a whole and has also lost sight of the prominence of Compound A in it.&rdquo;</p><p>An interim injunction was thus granted.</p><p><em>(2) Equivalence</em><br>In <em>Regen Lab v Estar</em> <a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2019/63.html target=_blank rel=noopener><strong>[2019] EWHC 63</strong></a>, the UK judge (Hacon HHJ) ruled on the doctrine of equivalents. This case relates to Regen&rsquo;s patent, claiming a method for the preparation of platelet rich plasma. Two key features of claim 1 relate to a polyester based thixotropic gel and a buffered sodium citrate solution at 0.1M.</p><p>The Defendants&rsquo; case on non-infringing was i) that the gel of their variant process was not polyester-based and ii) that their solution was at 0.136M and not 0.1M as required in claim 1.</p><p>Hacon HHJ took the reformulated Improver questions in sequence. After a &lsquo;yes&rsquo; to the first two questions, Hacon HHJ answered &rsquo;no&rsquo; to the third. He ruled: &ldquo;The evidence indicated that the molarity of the sodium citrate is not essential to the inventive concept and would not have been so regarded by the skilled person at the priority date&rdquo;. This would be different if there had been a sufficiently clear indication to the skilled person that strict compliance with the figure of 0.10M was intended. This was not the case.</p><p>Had the patent been valid, it would have been infringed.</p><p><em>(3) Plausibility and SPC&rsquo;s</em></p><p>The <em>Eli Lilly v Genentech</em> proceedings do not only relate to a (typical) patent revocation/infringement action, but also involved an issue on third-party SPC applications. The UK judge (Arnold J) started by saying that this case is &ldquo;one of the most complex patent cases I have ever tried&rdquo;. Thankfully, he reassured us, he has &ldquo;considerable experience of trying complex patent cases&rdquo;.</p><p>Genentech&rsquo;s patent relates to the IL-17A/F peptides and therapeutic uses thereof. While Genentech did not have a marketed product covered by its Patent, Lilly marketed an ixekizumab product: Taltz. Taltz is an antibody to interleukin-17 indicated for the treatment of psoriasis and psoriatic arthritis.</p><p>Starting with plausibility, <a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2019/387.html target=_blank rel=noopener><strong>[2019] EWHC 387</strong></a>, in relation to the medical use claims directed to psoriasis, Arnold J (as he then was) summarised the law as set out in <em>Warner-Lambert</em> [2018] UKSC 56. He noted that the application of plausibility depends on the context of the case. Taking this context into account (including the lack of relevant data in the patent), Arnold J (as he then was) held that the claim of therapeutic efficacy against psoriasis was speculative and that plausibility was not established.</p><p>As for the SPC, <a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2019/388.html target=_blank rel=noopener><strong>[2019] EWHC 388</strong></a>, Lilly sought a declaration that Genentech’s SPC was invalid. Arnold J considered the relevant provisions of the <a class=link href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32009R0469" target=_blank rel=noopener>SPC Regulation</a> to be unclear (whether or not the basic patent was considered to be valid). The question Arnold J referred to the CJEU, was: “Does the SPC Regulation preclude the grant of an SPC to the proprietor of a basic patent in respect of a product which is the subject of a marketing authorisation held by a third party without that party’s consent?”</p><p>By order of 5 September 2019, <a class=link href="http://curia.europa.eu/juris/liste.jsf?num=C-239/19&language=en" target=_blank rel=noopener><strong>C-239/19</strong></a>, the CJEU ruled that the request was inadmissible as it was not necessary to answer it as the basic patent had held to be invalid. Back to Arnold LJ (as he now is!), <a class=link href=https://uk.practicallaw.thomsonreuters.com/Document/IE6A66B50152911EABD70991115C8E5C2/View/FullText.html target=_blank rel=noopener><strong>[2019] EWHC 3260</strong></a>, he did not entertain further argument on the issue leaving it if necessary for appeal.</p><p><em>(4) Translations</em></p><p>In <em>Illumina v TDL Generics</em> <a class=link href="https://www.bailii.org/cgi-bin/format.cgi?doc=/ew/cases/EWHC/Patents/2019/1497.html" target=_blank rel=noopener><strong>[2019] EWHC 1497</strong></a>, the UK judge (Arnold J) ruled on the question whether the prior art was considered to be the abstract in Japanese or the English translation of the abstract. Arnold J considered: &ldquo;It was common ground between counsel that what mattered was how the original Japanese would be understood. I am doubtful this is correct, since the skilled person is located in the UK&rdquo; (referring to <em>Generics v Warner Lambert</em> <a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2015/2548.html target=_blank rel=noopener><strong>[2015] EWHC 2548</strong></a>). Arnold J ruled that the skilled person was deemed to read Ikeda in the English translation. However, Arnold J said, even if it was the meaning of the Japanese that was determinative, an English court had to rely on a translation in order to appreciate that meaning in any event.</p><p>In the end, this point was not influential to case in question. The patent has been held valid.</p><p>**A palate cleanser **</p><p>(5) Arrow declarations</p><p>In <em>Pfizer v F-Hoffmann La Roche</em> <a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2019/1520.html target=_blank rel=noopener><strong>[2019] EWHC 1520</strong></a>, the UK judge (Birss J) ruled on arrow declarations. In this case, Pfizer claimed that its proposed use (involving bevacizumab) lacked novelty and/or was obvious at the earliest relevant date and requested a so called Arrow-declaration (see: <a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2007/1900.html target=_blank rel=noopener><strong>[2007] EWHC 1900</strong></a>). Roche had patents covering Roche&rsquo;s proposed use. After Pfizer initiated legal proceedings, Roche de-designated the UK from all relevant patent families. However, now that Roche done so, it this absence of protection in the UK sufficient to prevent the granting of such declaration?</p><p>Birss J ruled that although Roche had no patent protection in the UK, such declaration might help Pfizer to defend itself against suits brought by Roche in other European countries. Thus, &ldquo;the true purpose of an Arrow declaration in this case would be for it to be used in foreign courts&rdquo;. This is not sufficient to Birss J.</p><p>No Arrow declaration was granted.</p><p><em>(6) Enablement</em></p><p>In <em>Takeda v Hoffmann-La Roche</em> <strong><a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2019/1911.html target=_blank rel=noopener>[2019] EWHC 1911</a></strong> , the UK judge (Birss J) ruled about enablement. The issue of law concerned what exactly needs to be enabled by the prior art. Must it be the very thing disclosed (as Roche (the patentee) argued) or is it sufficient if a skilled person would produce something different from the prior art which still fell within the claims (as Takeda argued)? </p><p>In this case, the issue was that the skilled person could not make the same antibody as referred to as &lsquo;Anti-D1&rsquo; in the prior art. There was insufficient information to do so. Roche contended that means the patent (claim 1) is novel. Birss J disagreed. He held that the relevant prior art is an enabling disclosure because a skilled person given that disclosure is able to make a version of Anti-D1 without an undue burden. He continued: &ldquo;It would be a great deal of work and it would not be identical to the antibody which the authors of [the relevant prior art] but from all the evidence in this case it is clear that a skilled team seeking to make their own version of Anti-D1 would succeed.</p><p>Birss J ruled that there was an anticipated disclosure.</p><p>**The main course – Supreme Court cases **</p><p><em>(7) Obvious to try</em></p><p>In the case <em>Actavis v ICOS</em> <a class=link href=https://www.bailii.org/uk/cases/UKSC/2019/15.html target=_blank rel=noopener><strong>[2019] UKSC 15</strong></a>, the UK Supreme Court reviewed the approach to obvious to try. Earlier, the Court of Appeal (<a class=link href=https://www.bailii.org/ew/cases/EWCA/Civ/2017/1671.html target=_blank rel=noopener><strong>[2017] EWCA Civ 1671</strong></a>) ruled that based on the trial judge&rsquo;s factual findings (<a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2016/1955.html target=_blank rel=noopener><strong>[2016] EWHC 1955</strong></a>), claim 7 should be held obvious. Claim 7 was directed to the treatment of sexual disfunction by administration of a dose no more than 5mg tadalafil per day. ICOS&rsquo; invention is finding that that dose is effective with minimal side effects.</p><p>ICOS argued that the correct question to be asked was whether at the priority date, before the skilled team embarked on any testing, it was obvious in the light of the prior art that a 5mg daily dose of Tadalafil would be safe and effective with minimal side effects. However, the Supreme Court held that it is not necessary for the skilled team to identify the specific dose in advance of the clinical testing. The skilled team would very likely test a 5mg dose given that the aim of a dose ranging study is to identify a dose as low as possible consistent with effectiveness.</p><p>In addition to the often cited passage of Kitchin J in Generics v H Lundbeck (<a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2007/1040.html target=_blank rel=noopener><strong>[2007] EWHC 1040</strong></a>) on the factors for obviousness, Lord Hodge added “the routineness of the research”.</p><p>ICOS&rsquo; patent for a Tadalafil dosing regime was held to be invalid.</p><p><em>(8) Inventor compensation</em></p><p>In the case <em>Shanks v Unilever</em> <a class=link href=https://www.bailii.org/uk/cases/UKSC/2019/45.html target=_blank rel=noopener>[<strong>2019] UKSC 45</strong></a>, the UK Supreme Court ruled on inventor compensation. This case was initiated by the employee (Prof. Shanks) who applied for compensation on the basis that the inventions Shank made had been of outstanding benefit to Unilever and that Prof. Shanks was entitled to a fair share of that benefit.</p><p>Where the judge starts by considering that the employee, Prof. Shanks, &ldquo;initially received a salary of £18,000 per annum and a Volvo car&rdquo;, one might guess what the outcome of this case will be. Especially when the Supreme Court continues to consider that Prof. Shanks &ldquo;built the first prototype of his invention at home using Mylar film and slides from his daughter’s toy microscope kit, and bulldog clips to hold the assembly together&rdquo;.</p><p>The Supreme Court held that an employee who makes an invention which belongs to his or her employer from the outset and for which a patent has been granted is entitled to compensation if he or she establishes:</p><p>i) that the patent is, having regard among other things to the size and nature of the employer’s undertaking, of outstanding benefit to the employer; and<br>ii) that, by reason of these matters, it is just that he or she be awarded compensation.</p><p>The employee, prof. Shanks, received an overall award of £2 million.</p><p>**Dessert **</p><p><em>(9) FRAND cases</em></p><p>Andrew also provided some &lsquo;snapshots&rsquo; of what has happened since the FRAND ruling in <em>Unwired Planet v Huawei</em> <a class=link href=https://www.bailii.org/ew/cases/EWCA/Civ/2018/2344.html target=_blank rel=noopener><strong>[2018] EWCA Civ 2344</strong></a>. The snapshots relate to the following cases:</p><p>1. <em>Conversant v Huawei</em> (Floyd LJ)</p><p>2. <em>TQ Delta v ZyXEL</em> (Floyd LJ)</p><p>3. <em>IPCom v Xiaomi</em> (Hacon HHJ)</p><p>4_. IPCom v Vodafone_ (Birss J)</p><ol start=5><li><em>IPCom v Lenovo</em> (Hacon HHJ)</li></ol><p>6. <em>Vestel v Advance and Philips</em> (Hacon HHJ)</p><p>Andrew concluded by mentioning that two important FRAND judgments are awaited:<br><em>Unwired Planet v Huawei</em> and <em>Philips v Asus and HTC</em>.</p><p><strong>(10) A few mince pies</strong></p><p>Andrew finished with commenting on some decisions of lesser importance but worthy of note:</p><p>1. <em>L&rsquo;Oreal v Liqwd</em> <a class=link href="https://www.hoganlovells.com/~/media/hogan-lovells/pdf/2019/loreal-v-olaplex-judgment--20191118.pdf?la=en" target=_blank rel=noopener><strong>[2019] EWCA CIV 1943</strong></a> (Arnold LJ & David LJ)</p><p> - about late advanced construction and new evidence;</p><p>2. <em>Anan Kasei v Neo Chemicals</em> <strong><a class=link href="https://www.bailii.org/cgi-bin/format.cgi?doc=/ew/cases/EWCA/Civ/2019/1646.html" target=_blank rel=noopener>[2019] EWCA Civ 1646</a></strong> (Floyd & Lewison LLJ)</p><p> - about ambiguity, insufficiency and uncertainty;</p><p>3. <em>Conversant v Apple</em> <strong><a class=link href=https://www.bailii.org/ew/cases/EWHC/Patents/2019/3266.html target=_blank rel=noopener>[2019] EWHC 3266</a></strong> (Birss J)</p><p> - about the identity of the skilled person post amendment;</p><p>4_. Conversant v Huawei_ [2019] EWHC 3130 (Arnold LJ)</p><p>-  about costs in case of a win on only one point; "</p></section><footer class=article-footer><section class=article-copyright><svg xmlns="http://www.w3.org/2000/svg" class="icon icon-tabler icon-tabler-copyright" width="24" height="24" viewBox="0 0 24 24" stroke-width="2" stroke="currentcolor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"/><circle cx="12" cy="12" r="9"/><path d="M14.5 9a3.5 4 0 100 6"/></svg><span>Licensed under CC BY-NC-SA 4.0</span></section></footer></article><footer class=site-footer><script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-3987358164777632" crossorigin=anonymous></script>
<script data-name=BMC-Widget src=https://cdn.buymeacoffee.com/widget/1.0.0/prod/widget.prod.min.js data-id=0x000216 data-description=coffee! data-message=coffee! data-color=#FF813F data-position=right data-x_margin=28 data-y_margin=18></script></footer><div class=pswp tabindex=-1 role=dialog aria-hidden=true><div class=pswp__bg></div><div class=pswp__scroll-wrap><div class=pswp__container><div class=pswp__item></div><div class=pswp__item></div><div class=pswp__item></div></div><div class="pswp__ui pswp__ui--hidden"><div class=pswp__top-bar><div class=pswp__counter></div><button class="pswp__button pswp__button--close" title="Close (Esc)"></button>
<button class="pswp__button pswp__button--share" title=Share></button>
<button class="pswp__button pswp__button--fs" title="Toggle fullscreen"></button>
<button class="pswp__button pswp__button--zoom" title="Zoom in/out"></button><div class=pswp__preloader><div class=pswp__preloader__icn><div class=pswp__preloader__cut><div class=pswp__preloader__donut></div></div></div></div></div><div class="pswp__share-modal pswp__share-modal--hidden pswp__single-tap"><div class=pswp__share-tooltip></div></div><button class="pswp__button pswp__button--arrow--left" title="Previous (arrow left)"></button>
<button class="pswp__button pswp__button--arrow--right" title="Next (arrow right)"></button><div class=pswp__caption><div class=pswp__caption__center></div></div></div></div></div><script src=https://cdn.jsdelivr.net/npm/photoswipe@4.1.3/dist/photoswipe.min.js integrity="sha256-ePwmChbbvXbsO02lbM3HoHbSHTHFAeChekF1xKJdleo=" crossorigin=anonymous defer></script><script src=https://cdn.jsdelivr.net/npm/photoswipe@4.1.3/dist/photoswipe-ui-default.min.js integrity="sha256-UKkzOn/w1mBxRmLLGrSeyB4e1xbrp4xylgAWb3M42pU=" crossorigin=anonymous defer></script><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/photoswipe@4.1.3/dist/default-skin/default-skin.css integrity="sha256-c0uckgykQ9v5k+IqViZOZKc47Jn7KQil4/MP3ySA3F8=" crossorigin=anonymous><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/photoswipe@4.1.3/dist/photoswipe.css integrity="sha256-SBLU4vv6CA6lHsZ1XyTdhyjJxCjPif/TRkjnsyGAGnE=" crossorigin=anonymous></main></div><script src=https://cdn.jsdelivr.net/npm/node-vibrant@3.1.5/dist/vibrant.min.js integrity="sha256-5NovOZc4iwiAWTYIFiIM7DxKUXKWvpVEuMEPLzcm5/g=" crossorigin=anonymous></script><script type=text/javascript src=/ts/main.js defer></script>
<script>(function(){const e=document.createElement("link");e.href="https://fonts.googleapis.com/css2?family=Lato:wght@300;400;700&display=swap",e.type="text/css",e.rel="stylesheet",document.head.appendChild(e)})()</script></body></html>